Refractory Lymphoma Clinical Trials

64 clinical trials for Refractory Lymphoma across international registries, including 9 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma — RECRUITING · PHASE1
• Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia — RECRUITING · PHASE2
• GB5005 CART-cell Injection in the Treatment of Patients With CD19-positive RR B-NHL — RECRUITING · PHASE1
• Epco, Zanu, Ritux for R/R FL or MZL — RECRUITING · PHASE2
• Avo In R/R And Previously Untreated MCL — RECRUITING · PHASE1
• Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma — RECRUITING · PHASE1
• Axicabtagene Ciloleucel Injection in Patients With Relapsed/Refractory Follicular Lymphoma — RECRUITING · PHASE2
• Solving Riddles Through Sequencing — RECRUITING
• A Study of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid Tumor — RECRUITING · PHASE1
• Testing LOXO-101 as Potentially Targeted Treatment in Cancers With NTRK Genetic Changes (MATCH - Subprotocol Z1E) — ACTIVE_NOT_RECRUITING · PHASE2
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) — ACTIVE_NOT_RECRUITING · PHASE2
• Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial — ACTIVE_NOT_RECRUITING · PHASE2
• Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I) — ACTIVE_NOT_RECRUITING · PHASE2
• Salvage Treatment With Glofitamab in R/R B-NHL: a GIMEMA-FIL Study — COMPLETED
• Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2) — ACTIVE_NOT_RECRUITING · PHASE2
• Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1) — ACTIVE_NOT_RECRUITING · PHASE2
• Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V) — ACTIVE_NOT_RECRUITING · PHASE2
• Testing Palbociclib (PD-0332991) as Potentially Targeting Treatment in Cancers With CDK4 or CDK6 Amplification (MATCH - Subprotocol Z1C) — ACTIVE_NOT_RECRUITING · PHASE2
• Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A) — ACTIVE_NOT_RECRUITING · PHASE2
• Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification (MATCH-Subprotocol Z1B) — ACTIVE_NOT_RECRUITING · PHASE2
• Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H) — ACTIVE_NOT_RECRUITING · PHASE2
• Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study — WITHDRAWN · PHASE1
• Testing Ipatasertib as Potentially Targeted Treatment in Cancers With AKT Genetic Changes (MATCH - Subprotocol Z1K) — ACTIVE_NOT_RECRUITING · PHASE2
• Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2) — ACTIVE_NOT_RECRUITING · PHASE2
• Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1) — ACTIVE_NOT_RECRUITING · PHASE2
• Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E) — ACTIVE_NOT_RECRUITING · PHASE2
• Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T) — ACTIVE_NOT_RECRUITING · PHASE2
• Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Expression (MATCH - Subprotocol Z1H) — ACTIVE_NOT_RECRUITING · PHASE2
• Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Loss of Expression (MATCH-Subprotocol P) — ACTIVE_NOT_RECRUITING · PHASE2
• Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N) — ACTIVE_NOT_RECRUITING · PHASE2
• Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH - Subprotocol Z1L) — ACTIVE_NOT_RECRUITING · PHASE2
• Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With mTOR Genetic Changes (MATCH - Subprotocol L) — ACTIVE_NOT_RECRUITING · PHASE2
• Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With TSC1 or TSC2 Genetic Changes (MATCH - Subprotocol M) — ACTIVE_NOT_RECRUITING · PHASE2
• Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q) — ACTIVE_NOT_RECRUITING · PHASE2
• Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F) — ACTIVE_NOT_RECRUITING · PHASE2
• Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R) — ACTIVE_NOT_RECRUITING · PHASE2
• Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U) — ACTIVE_NOT_RECRUITING · PHASE2
• Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A) — ACTIVE_NOT_RECRUITING · PHASE2
• Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I) — ACTIVE_NOT_RECRUITING · PHASE2
• Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y) — ACTIVE_NOT_RECRUITING · PHASE2
• Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F) — ACTIVE_NOT_RECRUITING · PHASE2
• Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G) — ACTIVE_NOT_RECRUITING · PHASE2
• Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B) — ACTIVE_NOT_RECRUITING · PHASE2
• Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1) — ACTIVE_NOT_RECRUITING · PHASE2
• Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors — ACTIVE_NOT_RECRUITING · PHASE1
• Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T) — COMPLETED · NA
• Radiation Post-CAR T in Refractory Lymphoma — TERMINATED · NA
• Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas — COMPLETED · PHASE1
• Pevonedistat, Irinotecan, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma — COMPLETED · PHASE1
• Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M) — WITHDRAWN · PHASE2

Refine this search